| Title: |
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium |
| Authors: |
Nasreddine, Rakan; Florence, Eric; Yombi, Jean Cyr; Henrard, Sophie; Darcis, Gilles; Van Praet, Jens; Vandekerckhove, Linos D.; Allard, Sabine; Demeester, Remy; MESSIAEN, Peter; Ausselet, Nathalie; Delforge, Marc; De Wit, Stephane |
| Contributors: |
Nasreddine, Rakan/0000-0002-1265-1500; Van Praet, Jens; Tomas/0000-0002-7125-7001; Darcis, Gilles/0000-0001-8192-1351; Nasreddine, Rakan; Florence, Eric; Yombi, Jean Cyr; Henrard, Sophie; Darcis, Gilles; Vandekerckhove, Linos D.; Allard, Sabine; Demeester, Remy; MESSIAEN, Peter; Ausselet, Nathalie; Delforge, Marc; De Wit, Stephane |
| Publisher Information: |
WILEY |
| Publication Year: |
2023 |
| Collection: |
Document Server@UHasselt (Universiteit Hasselt) |
| Subject Terms: |
bictegravir/emtricitabine/tenofovir alafenamide; efficacy; HIV; real-world data; tolerability |
| Description: |
Objectives: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real-world setting in Belgium.Methods: This was a retrospective, multicentre cohort study involving adult treatment-naive (TN) and treatment-experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV-1 viral load 200 copies/mL after being virologically suppressed) by week 48 and analysis of resistance-associated mutations at time of LVS; tolerability of BIC/FTC/TAF over the 48-week study period; and change in weight and proportion of participants reporting a >10% weight gain at week 48.Results: Overall, 2001 participants were included. Through 48 weeks, overall rate of virological suppression was 93.5%, with similar results observed in the following subgroups: age =50 years (92.7%), women (92.8%), Black sub-Saharan African (91%), TN (94%), TE (93.2%), and non-suppressed at baseline (86.6%). LVS was observed in 0.7% (n = 14) of participants, with one participant developing resistance-associated mutations to nucleoside reverse transcriptase inhibitors (184 V) and integrase strand transfer inhibitors (263KR). Of the 131 (6.5%) treatment discontinuations, the most common reason was an adverse event (2.4%), with the most frequent being central nervous system/psychiatric (0.4%) and gastrointestinal (0.4%) toxicity. Median weight gain at week 48 was 2 kg (interquartile range -1 to 5), and a >10% weight increase was observed in 11.6% of participants.Conclusion: In this large real-world cohort, BIC/FTC/TAF showed excellent virological efficacy in a diverse population of patients with HIV. Rare occurrence of emergent drug resistance was observed, and treatment was well tolerated. ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://hdl.handle.net/1942/40272; 924; 914; 24; 000967527300001 |
| DOI: |
10.1111/hiv.13493 |
| Availability: |
https://hdl.handle.net/1942/40272; https://doi.org/10.1111/hiv.13493 |
| Accession Number: |
edsbas.56BF4F8C |
| Database: |
BASE |